Abstract:Background: The aim of this systematic review was to compare clinical, radiographic and patient-reported outcomes (PROMs) in intra-bony defects treated with regenerative surgery or access flap. Materials and Methods: A systematic review protocol was written following the PRISMA checklist. Electronic and hand searches were performed to identify randomized clinical trials (RCTs) on regenerative treatment of deep intra-bony defects (≥3 mm) with a follow-up of at least 12 months. Primary outcome variables were pro… Show more
“…The CAL gains and PPD reductions reported in the present investigation in both groups were modest in comparison with other studies evaluating different regenerative technologies (Matarasso et al., 2015; Nibali et al., 2019). These limited clinical improvements may be explained by the patient and defect selection, since only one‐ and two‐wall non‐contained intraosseous lesions were selected, with the objective of assessing the added value of MSCs in the treatment of those defects lacking a predictable regenerative outcome.…”
Aim: To evaluate the safety and efficacy of autologous periodontal ligament-derived mesenchymal stem cells (PDL-MSCs) embedded in a xenogeneic bone substitute (XBS) for the regenerative treatment of intra-bony periodontal defects. Material and Methods: This quasi-randomized controlled pilot phase II clinical trial included patients requiring a tooth extraction and presence of one intra-bony lesion (1-2 walls). Patients were allocated to either the experimental (XBS + 10 × 10 6 PDL-MSCs/100 mg) or the control group (XBS). Clinical and radiographical parameters were recorded at baseline, 6, 9 and 12 months. The presence of adverse events was also evaluated. Chi-square, Student's t test, Mann-Whitney U, repeated-measures ANOVA and regression models were used. Results: Twenty patients were included. No serious adverse events were reported. Patients in the experimental group (n = 9) showed greater clinical attachment level (CAL) gain (1.44, standard deviation [SD] = 1.87) and probing pocket depth (PPD) reduction (2.33, SD = 1.32) than the control group (n = 10; CAL gain = 0.88, SD = 1.68, and PPD reduction = 2.10, SD = 2.46), without statistically significant differences. Conclusion: The application of PDL-MSCs to XBS for the treatment of one-to two-wall intra-bony lesions was safe and resulted in low postoperative morbidity and appropriate healing, although its additional benefit, when compared with the XBS alone, was not demonstrated.
“…The CAL gains and PPD reductions reported in the present investigation in both groups were modest in comparison with other studies evaluating different regenerative technologies (Matarasso et al., 2015; Nibali et al., 2019). These limited clinical improvements may be explained by the patient and defect selection, since only one‐ and two‐wall non‐contained intraosseous lesions were selected, with the objective of assessing the added value of MSCs in the treatment of those defects lacking a predictable regenerative outcome.…”
Aim: To evaluate the safety and efficacy of autologous periodontal ligament-derived mesenchymal stem cells (PDL-MSCs) embedded in a xenogeneic bone substitute (XBS) for the regenerative treatment of intra-bony periodontal defects. Material and Methods: This quasi-randomized controlled pilot phase II clinical trial included patients requiring a tooth extraction and presence of one intra-bony lesion (1-2 walls). Patients were allocated to either the experimental (XBS + 10 × 10 6 PDL-MSCs/100 mg) or the control group (XBS). Clinical and radiographical parameters were recorded at baseline, 6, 9 and 12 months. The presence of adverse events was also evaluated. Chi-square, Student's t test, Mann-Whitney U, repeated-measures ANOVA and regression models were used. Results: Twenty patients were included. No serious adverse events were reported. Patients in the experimental group (n = 9) showed greater clinical attachment level (CAL) gain (1.44, standard deviation [SD] = 1.87) and probing pocket depth (PPD) reduction (2.33, SD = 1.32) than the control group (n = 10; CAL gain = 0.88, SD = 1.68, and PPD reduction = 2.10, SD = 2.46), without statistically significant differences. Conclusion: The application of PDL-MSCs to XBS for the treatment of one-to two-wall intra-bony lesions was safe and resulted in low postoperative morbidity and appropriate healing, although its additional benefit, when compared with the XBS alone, was not demonstrated.
“…For this guideline, a total of 15 systematic reviews (SRs) were conducted to support the guideline development process (Carra et al., 2020; Dommisch, Walter, Dannewitz, & Eickholz, 2020; Donos et al., 2019; Figuero, Roldan, et al., 2019; Herrera et al., 2020; Jepsen et al., 2019; Nibali et al., 2019; Polak et al., 2020; Ramseier et al., 2020; Salvi et al., 2019; Sanz‐Sanchez et al., 2020; Slot, Valkenburg, & van der Weijden, 2020; Suvan et al., 2019; Teughels et al., 2020; Trombelli et al., 2020). The corresponding manuscripts are published within this special issue of the Journal of Clinical Periodontology.…”
On behalf of the EFP Workshop Participants and Methodological Consultants EFP Workshop Participants and Methodological Consultants are presented in Appendix 1.
“…With the currently available regeneration procedures, materials and technologies, intra-bony defects can be successfully regenerated, subject to patient factors such as plaque control, smoking and medical history, as well as tooth mobility, restorative and endodontic condition (Nibali et al, 2019). Several publications reported on the superiority of periodontal regenerative therapy in the treatment of intra-bony defects over the conventional surgeries such as periodontal access flap, known as open-flap debridement surgery (OFD), in terms of probing pocket depth (PPD) and clinical attachment loss (CAL) reductions (Castro et al, 2017;Needleman et al, 2006;Nibali et al, 2019).…”
Classically, periodontal defects have been differentiated based on bone resorption patterns into "supraosseous" ("suprabony") and "infraosseous" ("infrabony") (Goldman & Cohen, 1958). These authors defined suprabony defects as those where the base of the pocket is located coronal to the alveolar crest. On the other hand, infrabony defects are those with apical location of the base of the
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.